COVID-19 in pemphigus vulgaris patients with previous rituximab therapy: A tele-medicine experience.
COVID-19 in pemphigus vulgaris patients with previous rituximab therapy: A tele-medicine experience. J Dermatolog Treat. 2020 Jun 27;:1-7 Authors: Shahidi-Dadras M, Abdollahimajd F, Ohadi L, Tabary M, Araghi F, Mozafari N, Toosi P, Dadkhahfar S Abstract Nowadays, rituximab, an anti-CD20 monoclonal antibody, has revolutionized the treatment of moderate to severe pemphigus from both safety and efficacy perspectives. We aimed to perform a tele-dermatology study to evaluate the development of COVID-19 or its associated symptoms in pemphigus vulgaris (PV) patients who received rituximab treatment within five years from the initiation of pandemic. This cross-sectional study was performed on May 2020 with tele-medicine follow-up method in our center. Patients with PV who received rituximab treatment between 2014 and 2020 in our hospital were enrolled. Presence of COVID-19 symptoms or confirmed history of COVID-19 infection was recorded. We evaluated the records of 167 patients who received rituximab in our hospital. Out of Among these patients, 45 (26.9%) received rituximab within a year from the current pandemic. We identified 5 (4 female) cases of COVID-19 confirmed with computerized tomography (CT) scan with a mean age of 41.8 ± 9.6, and none of them have received rituximab within a year from the current pandemic. Among these 5 patients, 4 cases presented with COVID-19 symptoms. One case was asymptomatic and she was diagnosed accidentally...
I’m hopeful that some lasting changes for the better will come out of COVID-19 because that’s a common thread in human history.
ConclusionsThe presence of abnormal18F-FDG uptake adjacent to the ischial tuberosities together with findings at the peri-articular shoulder or interspinous bursa on whole-body PET/CT is highly sensitive and specific for a diagnosis of PMR.Trial registrationClinical Trial Registration: Australian New Zealand Clinical Trials Registry,http://www.anzctr.org.au, ACTRN1261400696695
ConclusionIn order to overcome those key challenges arising from CT datasets and solve some of the main problems existing in the current deep learning-based methods, we propose a novel unified CTumorGAN framework, which can be effectively generalized to address any kinds of tumor datasets with superior performance.
Authors: Pathania YS, Bhardwaj A PMID: 32723116 [PubMed - as supplied by publisher]
The conventional treatment mainstays for pemphigus are problematic during the COVID-19 pandemic, and a shift in disease management strategy is in order.Medscape Medical News
Abstract The novel coronavirus is rapidly spreading around the world. Since the public announcement of the COVID-19 outbreak, several concerns have been raised by dermatologists as well as pemphigus patients who take immunosuppressive drugs. In this paper, we review the literature about the common treatment of pemphigus with a focus on the lessons from similar epidemics to find a proper suggestion to manage pemphigus in the COVID-19 pandemic era. The effect of many of the drugs used for treatment of Pemphigus vulgaris (PV) on COVID-19 is not clear. We also do not have data on the impact of this autoimmune disease,...
To the Editor: We read with interest the recent Journal of the American Academy of Dermatology commentary by Shakshouk et al1 regarding treatment considerations for pemphigus patients. The effect of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) on the burden of disease and quality of life in patients with chronic inflammatory dermatologic conditions has been tremendous. Herein we highlight special con siderations for caring for atopic dermatitis patients and minimizing flares during this time (Table I).